Percutaneous coronary interventions in Europe in 2006

Abstract

Aims The purpose of this registry is to collect data on trends in interventional cardiology within Europe. Special interest focuses on relative increases and ratios in newer re-vascularisation approaches and its distribution in different regions in Europe. We report the data of the year 2001 and give an overview of the development of coronary interventions since 1992, when the first data collection was performed. Methods and Results Questionnaires were distributed to delegates of the individual national societies of cardiology represented in the European Society of Cardiology. These were completed by the local institutions and operators and showed that 1,806,238 angiograms and 617,176 percutaneous transluminal coronary angioplasties (PTCAs) were performed in 2001. This is an increase of 10% and 17%, respectively, compared with the year 2000. The population-adjusted PTCA rate rose from nearly 800 procedures per 10 6 inhabitants in the year 2000 to approximately 990 procedures per 10 6 inhabitants in 2001. Coronary stenting increased by 25% to about 488,900 stents implanted in 2001. Complication rates remained unchanged, and the need for emergency coronary artery bypass grafting is still at 0.2% per percutaneous intervention. Conclusion Interventional cardiology in Europe is still expanding, mainly due to rapid growth in countries with lower socio-economical levels. Most central European countries reported only minor increases in procedures performed. Coronary stenting remains the only noteworthy adjunctive strategy to balloon angioplasty.

Reimbursement and the Practice of Cardiology

“…1). The resulting per-capita number of procedures by far outstrip the corresponding figures in other European countries (8), including those with similar healthcare standards (Fig. 2).…”

Impacto da disponibilização de stents farmacológicos para pacientes do Sistema Único de Saúde nas indicações de revascularização miocárdica

“…[11][12][13] Em artigo publicado em 2010, Moschovitis et al 14 detalham o registro europeu de procedimentos realizados em 2006, chamando a atenção para o porcentual de SFs já utilizado àquela época em países como Itália (88%), Suíça (82%) e também no Reino Unido (64%). As Diretrizes de Revascularização Miocárdica da Sociedade Europeia de Cardiologia 4 indicam como classe I, nível de evidência A o uso de SFs com eficácia a longo prazo comprovada (sirolimus, paclitaxel e zotarolimus) como endoprótese padrão para utilização em todos os casos, exceto em determinadas condições em que haja preocupação ou contraindicação para o uso prolongado de terapia antiplaquetária dupla.…”

A pilot randomized trial of pentoxifylline for the reduction of periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention

“…During the last years, the number of percutaneous coronary intervention (PCI) procedures has increased all over the world due to its potential role in the management of ischemic heart diseases (IHD) [1][2][3]. Despite the recent technical and medical advances in the performance of PCI, it contains some adverse clinical outcomes [4].…”